...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Urologic oncology >A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or insignificant
【24h】

A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or insignificant

机译：根治性前列腺切除术后生化复发的单一机构经验，对于病理学上小或微不足道的肿瘤

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: Small volume prostate cancers (<0.5 cc, svPC), and insignificant prostate cancers (<0.5 cc and Gleason scores <7, InsigPC) are considered clinically insignificant by some investigators. The aim of this study is to determine the biochemical recurrence rate (BCR) of svPC and InsigPC in prostatectomy specimens. METHODS: In total, 502 patients with prostate cancer, treated with radical prostatectomy (RP) between 1992 and 2005 and with detailed pathological classification, were included in the present study. Patients were postoperatively followed for a median period of 39.5 months (0.6-150). A total of 82 specimens (16.3%) with svPC including 64 (12.8%) with InsigPC were identified. BCR was defined as 2 consecutive PSA levels >0.10 ng/ml. RESULTS: In the total group, the median age at the time of surgery was 62.7 years (42.4-73.4) and the median preoperative PSA level was 8.0 ng/ml. Patients with InsigPC had Gleason scores of 4 in 7%, 5 in 37%, and 6 in 56%. Positive surgical margins were identified in 13 (15.9%) svPC and in 8 (12.7%) InsigPC specimens. The 5-year risk of BCR for the svPC group and the insigPC group was 10% (95% CI 2-18%, 7 and 5 patients, respectively) vs. 35% (95% CI 29-41%) in the rest of the cohort (log rank P = 0.001). CONCLUSION: Patients with svPC and patients with InsigPC have a significantly lower risk of BCR. However, even in this seemingly very favorable patient group, 1 in 10 patients will develop a BCR after RP. Therefore, new studies are needed to examine what the prognostic relevance is of small-volume tumors.
机译：目的：一些研究者认为小体积前列腺癌（<0.5 cc，svPC）和微不足道的前列腺癌（<0.5 cc，Gleason评分<7，InsigPC）在临床上不重要。这项研究的目的是确定前列腺切除术标本中svPC和InsigPC的生化复发率（BCR）。方法：本研究共纳入502例前列腺癌患者，这些患者在1992年至2005年之间接受了根治性前列腺切除术（RP）治疗，并进行了详细的病理学分类。术后随访患者的中位时间为39.5个月（0.6-150）。总共鉴定出了svPC的82个标本（16.3％），包括InsigPC的64个（12.8％）。 BCR被定义为两个连续的PSA水平> 0.10 ng / ml。结果：在整个组中，手术时的中位年龄为62.7岁（42.4-73.4），术前PSA的中位值为8.0 ng / ml。 InsigPC患者的Gleason评分分别为7％，4、37％和5、56％，分别为7％和4。在13份（15.9％）svPC和8份（12.7％）InsigPC标本中，手术切缘阳性。 svPC组和insigPC组的5年BCR风险分别为10％（95％CI 2-18％，7和5例患者），而其余比例为35％（95％CI 29-41％）。队列的对数（对数等级P = 0.001）。结论：svPC患者和InsigPC患者的BCR风险显着降低。但是，即使在这个看似非常有利的患者组中，十分之一的患者在RP后也会发生BCR。因此，需要新的研究来检查小体积肿瘤的预后相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号